IBM Analysts Maintain Cautious Outlook Despite Strong Q1 Performance

Shares of IBM (NYSE: IBM) rose in early trading on Thursday, after the company reported better-than-expected earnings for the first quarter. Bernstein On IBM

Shares of IBM (NYSE:IBM) rose in early trading on Thursday, after the company reported better-than-expected earnings for the first quarter.

Bernstein On IBM

Analyst Toni Sacconaghi maintained a Market-Perform rating and price target of $145.

IBM’s first-quarter results were broadly in-line with the consensus estimates, Sacconaghi said in a note. “As expected, IBM reaffirmed its FY 2023 revenue and FCF targets, though it did broaden its expected revenue growth range to 3% – 5%,” he added.

IBM indicated a deceleration in consulting demand in the U.S., while there is no erosion in its consulting backlog, the analyst mentioned. “We note that Consulting historically has been a cyclical business, and we see some risk to 2H revenues from a potentially weaker macro environment,” he added.

Check out other analyst stock ratings.

Morgan Stanley On IBM

Analyst Erik Woodring reiterated an Equal-Weight rating, while reducing the price target from $143 to $135.

“IBM beat 1Q EPS and kept CY23 rev growth largely unchanged at 3-5% Y/Y in CC & $10.5B FCF, reflecting lower growth in Consulting and RHT, but stronger TPP,” Woodring said in a note.

Although IBM’s first-quarter results were better than feared, it needs a “strong 2H ramp” to meet its only slightly lowered earnings guidance for 2023, the analyst stated. “Lowered Consulting outlook reflects end of 1Q deterioration,” he added.

IBM Price Action: Shares of IBM had risen by 0.69% to $127.19 at the time of publishing Thursday.

Also Read: SpaceX Starship Launches, Boosters Fail To Separate: What Elon Musk Has To Say For Future

Photo: Unsplash

Total
0
Shares
Related Posts
Read More

Reported Late Wednesday, Ardelyx Announces FDA Advisory Committee Votes 9-To-4 That The Benefits Of XPHOZAH Outweigh Its Risks For The Control Of Serum Phosphorus In Adult Patients With Chronic Kidney Disease On Dialysis

The Advisory Committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders The Office of New Drugs is expected to provide a response to Ardelyx's appeal

ARDX

Read More

What’s Going On With Alaska Air Stock?

According to a report from the Wall Street Journal, it seems increasingly likely that the bolts required to secure the door plug to the aircraft were missing when the plane left the Boeing Company (NYSE:BA) factory in Renton, WA. According to sources, Boeing and industry officials believe that Boeing employees failed to replace the bolts after reinstalling the 737 Max 9 plug door after opening or removing it during production.

ALK